A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates

Current Pharmaceutical Design

Volumn 15, Issue 12, 2009, Pages 1295-1308

  Roycik, M D ^a   Fang, X ^b   Sang, Q X ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

^b JILIN UNIVERSITY   (China)

Author keywords

Adamalysins; ADAMTS; Cathepsins; Heparanase; Hyaluronidases; Kallikreins; Matrix metalloproteinases; Urokinase type plasminogen activator

Indexed keywords

ADAM PROTEIN; ADAMALYSIN; CATHEPSIN; HEPARANASE; HYALURONIDASE; KALLIKREIN; MATRIPTASE; MATRIX METALLOPROTEINASE; PLASMIN; PROSTATE SPECIFIC ANTIGEN; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; VASCULAR ENDOTHELIAL CADHERIN;

ADIPOGENESIS; ATHEROSCLEROSIS; BONE REMODELING; CARDIOVASCULAR DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME METABOLISM; ENZYME STRUCTURE; EXTRACELLULAR MATRIX; HUMAN; METASTASIS POTENTIAL; NONHUMAN; OBESITY; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TUMOR;

ANIMALS; CATHEPSINS; EXTRACELLULAR MATRIX; GLUCURONIDASE; HUMANS; HYALURONOGLUCOSAMINIDASE; HYDROLASES; KALLIKREINS; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; PLASMINOGEN ACTIVATORS; SERINE ENDOPEPTIDASES;

EID: 65649087873     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787846676     Document Type: Review

References (203)

1. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998; 76: 609-52.
2. Stamenkovic I. Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol 2003; 200: 448-64.
3. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6: 480-98.
4. López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007; 7: 800-8.
5. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, et al. Multistep pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 2007; 9: 893-904.
6. Bergan JJ, Schmid-Schönbein GW, Coleridge Smith PD, Nicolaides AJ, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med 2006; 555: 488-98.
7. Derosa G, Ferrari I, D'Angelo A, Tinelli C, Salvadeo SA, Ciccarelli L, et al. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 2008; 15: 219-24.
8. Raffetto JD, Khalil RA. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol 2008; 6: 158-72.
9. Rawlings ND, Barrett AJ. Evolutionary families of metallopeptidases. Methods Enzymol 1995; 248: 183-228.
10. Nagase H, Woesner JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
11. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990; 87: 5578-82.
12. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004; 16: 558-64.
13. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8: 221-33.
14. Schilling O, Overall CM. Proteomic discovery of protease substrates. Curr Opin Chem Biol 2007; 11: 36-45.
15. Bouloumié A, Sengenès C, Portolan G, Galitzky J, Lafontan M. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 2001; 50: 2080-6.
16. Chavey C, Mari B, Monthouel MN, Bonnafous S, Anglard P, Van Obberghen E et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem 2003; 278: 11888-96.
17. Bourlier V, Zakaroff-Girard A, De Barros S, Pizzacalla C, de Saint Front VD, Lafontan M et al. Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase-9 in human adipocyte differentiation. J Pharmacol Exp Ther 2005; 312: 1272-9.
18. De Barros S, Zakaroff-Girard A, Lafontan M, Galitzky J, Bourlier V. Inhibition of human preadipocytes proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9. J Pharmacol Exp Ther 2007; 320: 291-9.
19. Van Hul M, Lijnen HR. A functional role of gelatinase A in the development of nutritionarlly induced obesity in mice. J Thromb Haemost 2008; 6: 1198-206.
20. Blobel CP. Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. Cell 1997; 90: 589-92.
21. Zhang XP, Kamata T, Yokoyama K, Puzon-McLaughlin W, Takada Y. Specific interaction of the recombinant disintegrin-like domain MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. J Biol Chem 1998; 273: 7345-50.
22. Eto K, Huet C, Tarui T, Kupriyanov S, Liu HZ, Puzon-McLaughlin W et al. Functional classification of ADAMs based on a conserved motif for binding to integrin alpha 9beta1: implications for sperm-egg binding and other cell interactions. J Biol Chem 2002; 277: 17804-10.
23. Yuan R, Primakoff P, Myles DG. A role for the disintegrin domain of cyritestin, a sperm surface protein belonging to the ADAM family, in mouse sperm-egg plasma membrane adhesion and fusion. J Cell Biol 1997; 137: 105-12.
24. Yang P, Baker KA, Hagg T. A disintegrin and metalloprotease 21 (ADAM21) is associated with neurogenesis and axonal growth in developing and adult rodent CNS. J Comp Neurol 2005; 490: 163-79.
25. Manso AM, Elsherif L, Kang SM, Ross RS. Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling. Cardiovasc Res 2006; 69: 574-84.
26. Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 2008; 90: 369-79.
27. Andreini C, Banci L, Bertini I, Elmi S, Rosato A. Comparative analysis of the ADAM and ADAMTS families. J Proteome Res 2005; 4: 881-8.
28. Jones GC, Riley GP. ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Ther 2005; 7: 160-9.
29. Loechel F, Gilpin BJ, Engvall E, Albrechtsen R, Wewer UM. Human ADAM 12 (meltrin alpha) is an active metalloprotease. J Biol Chem 1998; 273: 16993-7.
30. Takeda S, Igarashi T, Mori H, Araki S. Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. EMBO J 2006; 25: 2388-96.
31. Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, López-Otín C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrain and thrombospondin-1 domains. Gene 2002; 283: 49-62.
32. Apte SS. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int J Biochem Cell Biol 2004; 36: 981-5.
33. Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J 2005; 386: 15-27.
34. Kuno K, Matsushima K. ADAMTS-1 protein anchors at the extracellular matrix through the thrombospondin type I motifs and its spacing region. J Biol Chem 1998; 273: 13912-7.
35. Tang BL, Hong W. ADAMTS: a novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats. FEBS Lett 1999; 445: 223-5.
36. Abbaszade I, Liu RQ, Yang F, Rosenfeld SA, Ross OH, Link JR et al. Cloning and characterization of ADAMTS11, an aggregcanase from the ADAMTS family. J Biol Chem 1999; 274: 23443-50.
37. Hurskainen TL, Hirohata S, Seldin MF, Apte SS. ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family. J Biol Chem 1999; 274: 25555-63.
38. Cal S, Arguelles JM, Fernandez PL, López-Otín C. Identification, characterization, and intracellular processing of ADAM-TS12, a novel human disintegrin with a complex structural organization involving multiple thrombospondin-1 repeats. J Biol Chem 2001; 276: 17932-40.
39. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-63.
40. Blelloch R, Kimble J. Control of organ shape by a secreted metalloprotease in the nematode Caenorhabditis elegans. Nature 1999; 399: 586-90.
41. Rodriguez-Manzaneque JC, Milchanowski AB, Dufour EK, Leduc R, Iruela-Arispe ML. Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms. J Biol Chem 2000; 275: 33471-9.
42. Jönsson-Rylander AC, Nilsson T, Fritsche-Danielson R, Hammarström A, Behrendt M, Andersson JO et al. Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. Arterioscler Thromb Vasc Biol 2005; 25: 180-5.
43. Bondeson J, Wainwright S, Hughes C, Caterson B. The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin Exp Rheumatol 2008; 26: 139-45.
44. Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N. Elevated concentration of soluble vascular endothelial cadherin is associated with coronary atherosclerosis. Cir J 2004; 68: 1-5.
45. Schulz B, Pruessmeyer J, Maretzky T, Ludwig A, Blobel CP, Saftig P et al. ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin. Circ Res 2008; 102: 1192-201.
46. Al-Fakhri N, Wilhelm J, Hahn M, Heidt M, Hehrlein FW, Endisch AM et al. Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis. J Cell Biochem 2003; 89: 808-23.
47. Canault M, Peiretti F, Kopp F, Bonardo B, Bonzi MR, Coudeyre JC et al. The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. Atherosclerosis 2006; 187: 82-91.
48. Canault M, Leroyer AS, Peiretti F, Lesèche G, Tedgui A, Bonardo B et al. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol 2007; 171: 1713-23.
49. Charrier-Hisamuddin L, Laboisse CL, Merlin D. ADAM-15: a metalloproteinase that mediates inflammation. FASEB J 2008; 22: 641-53.
50. Wågsäter D, Björk H, Zhu C, Björkegren J, Valen G, Hamsten A et al. ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis 2008; 196: 514-22.
51. Okada A, Mochizuki S, Yatabe T, Kimura T, Shiomi T, Fujita Y et al. ADAM-12 (meltrin alpha) is involved in chondrocyte proliferation via cleavage of insulin-like growth factor binding protein 5 in osteoarthritic cartilage. Arthritis Rheum 2008; 58: 778-89.
52. Tortorella MD, Malfait AM. Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis. Curr Pharm Biotechnol 2008; 9: 16-23.
53. Kevorkian L, Young DA, Darrah C, Donell ST, Shepstone L, Porter S et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rhemu 2004; 50: 131-41.
54. Kuno K, Okada Y, Kawashima H, Nakamura H, Miyasaka M, Ohno H et al. ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett 2000; 478: 241-5.
55. Colige A, Beschin A, Samyn B, Goebels Y, Van Beeumen J, Nusgens BV et al. Characterization and partial amino acid sequencing of a 107-kDa procollagen I N-proteinase purified by affinity chromatography on immobilized type XIV collagen. J Biol Chem 1995; 270: 16724-30.
56. Colige A, Li SW, Sieron AL, Nusgens BV, Prockop DJ, Lapiere CM. cDNA cloning and expression of bovine procollagen I N-proteinase: a new member of the superfamily of zinc-metalloproteinases with binding sites for cells and other matrix components. Proc Natl Acad Sci USA 1997; 94: 2374-9.
57. Wang WM, Lee S, Steiglitz BM, Scott IC, Lebares CC, Allen ML et al. Transforming growth factor-beta induces secretion of activated ADAMTS-2. A procollagen III N-proteinase. J Biol Chem 2003; 278: 19549-57.
58. Fernandes RJ, Hirohata S, Engle JM, Colige A, Cohn DH, Eyre DR et al. Procollagen II amino propeptide processing by ADAMTS-3. Insights on dermatosparaxis. J Biol Chem 2001; 276: 31502-9.
59. Tortorella MD, Pratta M, Liu R, Austin J, Ross OH, Abbaszade I et al. Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4). J Biol Chem 2000; 275: 18566-73.
60. Tortorella MD, Malfait AM, Deccico C, Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAMTS-5 (aggrecanse-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001; 9: 539-52.
61. Liu CJ, Kong W, Ilalov K, Yu S, Xu K, Prazak L et al. ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein. FASEB J 2006; 20: 988-90.
62. Collins-Racie LA, Flannery CR, Zeng W, Corcoran C, Annis-Freeman B, Agostino MJ et al. ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. Matrix Biol 2004; 23: 219-30.
63. Somerville RP, Longpre JM, Jungers KA, Engle JM, Ross M, Evanko S et al. Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1. J Biol Chem 2003; 278: 9503-13.
64. Somerville RP, Jungers KA, Apte SS. Discovery and characterization of a novel, widely expressed metalloprotease, ADAMTS10, and its proteolytic activation. J Biol Chem 2004; 279: 51208-17.
65. Liu CJ, Kong W, Xu K, Luan Y, Ilalov K, Sehgal B et al. ADAMTS-12 associates with and degrades cartilage oligomeric matrix protein. J Biol Chem 2006; 281: 15800-8.
66. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-6.
67. Colige A, Vandenberghe I, Thiry M, Lambert CA, Van Beeumen J, Li SW et al. Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3. J Biol Chem 2002; 277: 5756-66.
68. Yamaji N, Nishimura K, Abe K, Ohara O, Nagase T, Nomura N. Novel metalloprotease having aggrecanase activity. In Pat, Yamanouchi Pharmeutical Co. Ltd, Japan 2001.
69. Llamazares M, Cal S, Quesada V, López-Otín C. Identification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases- disintegrins with multiple thrombospondin-1 repeats and a unique GON domain. J Biol Chem 2003; 278: 13382-9.
70. Song RH, Tortorella MD, Malfait AM, Alston JT, Yang Z, Arner EC et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 2007; 56: 575-85.
71. Kuester D, Lippert H, Roessner A, Krueger S. The cathepsin family and their role in colorectal cancer. Pathol Res Pract 2008; 204: 491-500.
72. Riese RJ, Wolf PR, Brömme D, Natkin LR, Villadangos JA, Ploegh HL et al. Essential role for cathepsin S in MCH class II-associated invariant chain processing and peptide loading. Immunity 1996; 4: 357-66.
73. Nixon RA, Cataldo AM. The lysosomal system in neuronal cell death: a review. Ann N Y Acad Sci 1993; 679: 87-109.
74. Kamphuis IG, Kalk KH, Swarte MB, Drenth J. Structure of papain refined at 1.65 A resolution. J Mol Biol 1984; 179: 233-56.
75. Turk B, Turk V, Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem 1997; 378: 141-150.
76. Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 2000; 1477: 98-111.
77. Pinitglang S, Watts AB, Patel M, Reid JD, Noble MA, Gul S et al. A classical enzyme active center motif lacks catalytic competence until modulated electrostatically. Biochemistry 1997; 36: 9968-82.
78. Tao K, Stearns NA, Dong J, Wu QL, Sahagian GG. The proregion of cathepsin L is required for proper folding, stability, and ER exit. Arch Biochem Biophys 1994; 311: 19-27.
79. Kominami E, Tsukahara T, Hara K, Katunuma N. Biosyntheses and processing of lysosomal cysteine proteinases in rat macrophages. FEBS Lett 1988; 231: 225-8.
80. Nishimura Y, Kawabata T, Kato K. Identification of latent procathespins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Arch Biochem Biophys 1988; 261: 64-71.
81. Rowan AD, Mason P, Mach L, Mort JS. Rat procathepsin B. Proteolytic processing to the mature form in vitro. J Biol Chem 1992; 267: 15993-9.
82. Zavašnik-Bergant T, Turk B. Cysteine cathepsins in the immune response. Tissue Antigens 2006; 67: 349-55.
83. Koga H, Yamada H, Nishimura Y, Kato K, Imoto T. Multiple proteolytic action of rat liver cathepsin B: specificities and pH-dependences of the endo- and exopeptidases activities. J Biochem 1991; 110: 179-88.
84. Guncar G, Podobnik M, Pungercar J, Strukelj B, Turk V, Turk D. Crystal structure of porcine cathepsin H determined at 2.1 A resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function. Structure 1998; 6: 51-61.
85. Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998; 273: 32347-52.
86. Kafienah W, Brömme D, Buttle DJ, Croucher LJ, Hollander AP. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem J 1998; 331: 727-32.
87. Brömme D, Okamoto K, Wang BB, Biroc S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 1996; 271: 2126-32.
88. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996; 271: 12511-6.
89. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273: 1236-8.
90. Konttinen YT, Mandelin J, Li TF, Salo J, Lassus J, Liljeström M et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rhemu 2002; 46: 953-60.
91. Morko JP, Söderström M, Säämänen AM, Salminen HJ, Vuorio EI. Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis. Ann Rheum Dis 2004; 63: 649-55.
92. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102: 576-83.
93. Oörni K, Sneck M, Brömme D, Pentikäinen MO, Lindstedt KA, Mäyränpää M et al. Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. J Biol Chem 2004; 279: 34776-84.
94. Liu J, Sukhova GK, Yang JT, Sun J, Ma L, Ren A et al. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis 2006; 184: 302-11.
95. Yasuda Y, Li Z, Greenbaum D, Bogyo M, Weber E, Brömme D. Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. J Biol Chem 2004; 279: 36761-70.
96. Sukhova GK, Zhang Y, Pan JH, Wada Y, Yamamoto T, Naito M et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003; 111: 897-906.
97. Rodgers KJ, Watkins DJ, Miller AL, Chan PY, Karanam S, Brissette WH et al. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2006; 26: 851-6.
98. Lutgens E, Lutgens SP, Faber BC, Heeneman S, Gijbels MM, de Winther MP et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006; 113: 98-107.
99. Punturieri A, Filippov S, Allen E, Caras I, Murray R, Reddy V et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med 2000; 192: 789-99.
100. Gacko M, Chyczewski L, Chrostek L. Distribution, activity and concentration of cathepsin B and cystatin C in the wall of aortic aneurysm. Pol J Pathol 1999; 50: 83-6.
101. Gacko M, Glowiński S. Activities of proteases in parietal thrombus of aortic aneurysm. Clin Chim Acta 1998; 271: 171-7.
102. Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, Zhang Y et al. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res 2003; 92: 493-500.
103. Gacko M, Glowiński S. Cathepsin D and cathepsin L activities in aortic aneurysm wall and parietal thrombus. Clin Chem Lab Med 1998; 36: 449-52.
104. Burns-Kurtis CL, Olzinski AR, Needle S, Fox JH, Capper EA, Kelly FM et al. Cathepsin S expression is up-regulated following balloon angioplasty in the hypercholesterolemic rabbit. Cardiovasc Res 2004; 62: 610-20.
105. Cheng XW, Kuzuya M, Sasaki T, Arakawa K, Kanda S, Sumi D et al. Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. Am J Pathol 2004; 164: 243-51.
106. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104: 1191-7.
107. Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, Garcia M et al. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 2002; 21: 5951-5.
108. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006; 6: 764-5.
109. Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007; 6: 60-4.
110. Palermo C, Joyce JA. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 2008; 29: 22-8.
111. Vasiljeva O, Turk B. Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion. Biochimie 2008; 90: 380-6.
112. Csóka AB, Frost GI, Stern R. The six hyaluronidases-like genes in the human and mouse genomes. Matrix Biol 2001; 20: 499-508.
113. Stern R. Hyaluronidases in cancer biology. Semin Cancer Biol 2008; 18: 275-80.
114. Jedrzejas MJ, Stern R. Structures of vertebrate hyaluronidases and their unique enzymatic mechanism of hydrolysis. Proteins 2005; 61: 227-38.
115. Chao KL, Muthukumar L, Herzberg O. Structure of human hyaluronidase-1, a hyaluronan hydrolyzing enzyme involved in tumor growth and angiogenesis. Biochemistry 2007; 46: 6911-20.
116. Csóka AB, Frost GI, Wong T, Stern R. Purification and microsequencing of hyaluronidase isozymes from human urine. FEBS Lett 1997; 417: 307-10.
117. Stern R. Devising a pathway for hyaluronan catabolism: are we there yet? Glycobiology 2003; 12: 105R-15R.
118. Frost GI, Mohapatra G, Wong TM, Csóka AB, Gray JW, Stern R. HYALLUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA. Oncogene 2000; 19: 870-7.
119. Lokeshwar VB, Schroeder GL, Carey RI, Soloway MS, Iida N. Regulation of hyaluronidase activity by alternative mRNA splicing. J Biol Chem 2002; 277: 33654-63.
120. Junker N, Latini S, Petersen LN, Kristjansen PE. Expression and regulation patters of hyaluronidases in small cell lung cancer and glioma lines. Oncol Rep 2003; 10: 609-16.
121. Girish KS, Kemparaju K. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview. Life Sci 2007; 80: 1921-43.
122. Lepperdinger G, Strobl B, Kreil G. HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with novel type specificity. J Biol Chem 1998; 273: 22466-70.
123. Lepperdinger G, Müllegger J, Kreil G. Hyal2 - less active, but more versatile? Matrix Biol 2001; 20: 509-14.
124. Cherr GN, Yudin AI, Overstreet JW. The dual functions of GPI-anchored PH-20: hyaluronidase and intracellular signaling. Matrix Biol 2001; 20: 515-25.
125. Lokeshwar VB, Lokeshwar BL, Pham HT, Block NL. Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res 1996; 56: 651-7.
126. Madan AK, Pang Y, Wilkiemeyer MB, Yu D, Beech DJ. Increased hyaluronidase expression in more aggressive prostate adenocarcinoma. Oncol Rep 1999; 6: 1431-3.
127. Kovar JL, Johnson MA, Volcheck WM, Chen J, Simpson MA. Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am J Pathol 2006; 169: 1415-26.
128. Lokeshwar VB, Cerwinka WH, Lokeshwar BL. HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res 2005; 65: 2243-50.
129. Madan AK, Yu K, Dhurandhar N, Cullinane C, Pang Y, Beech DJ. Association of hyaluronidase and breast adenocarcinoma invasiveness. Oncol Rep 1999; 6: 607-9.
130. Beech DJ, Madan AK, Deng N. Expression of PH-20 in normal and neoplastic breast tissue. J Surg Res 2002; 103: 203-7.
131. Godin DA, Fitzpatrick PC, Scandurro AB, Belafsky PC, Woodworth BA, Amedee RG et al. PH20: a novel tumor marker for laryngeal cancer. Arch Otolaryngol Head Neck Surg 2000; 126: 402-4.
132. Lokeshwar VB, Selzer MG. Differences in hyaluronic acidmediated functions and signaling in arterial, microvessel, and veinderived human endothelial cells. J Biol Chem 2000; 275: 27641-9.
133. Takahashi Y, Li L, Kamiryo M, Asteriou T, Moustakas A, Yamashita H et al. Hyaluronan fragments induce endothelial cell differentiation in a CD44- and CXCL1/GRO1-dependent manner. J Biol Chem 2005; 280: 24195-204.
134. Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 2001; 276: 11922-32.
135. Franzmann EJ, Schroeder GL, Goodwin WJ, Weed DT, Fisher P, Lokeshwar VB. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer 2003; 106: 438-45.
136. Lokeshwar VB, Obek C, Soloway MS, Block NL. Tumorassociated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 1997; 57: 773-7.
137. Lokeshwar VB, Cerwinka WH, Isoyama T, Lokeshwar BL. HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res 2005; 65: 7782-9.
138. Aboughalia AH. Elevation of hyaluronidase-1 and soluble intercellular adhesion molecule-1 helps select bladder cancer patients at risk of invasion. Arch Med Res 2006; 37: 109-16.
139. Patel S, Turner PR, Stubberfield C, Barry E, Rohlff CR, Stamps A et al. Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer. Int J Cancer 2002; 97: 416-24.
140. Csóka AB, Frost GI, Heng HH, Scherer SW, Mohapatra G, Stern R. The hyaluronidase gene HYAL1 maps to chromosome 3p21.2- p21.3 in human and 9F1-F2 in mouse, a conserved candidate tumor suppressor locus. Genomics 1998; 48: 63-70.
141. Ghatak S, Misra S, Toole BP. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 2002; 277: 38013-20.
142. Jacobson A, Rahmanian M, Rubin K, Heldin P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer 2002; 102: 212-9.
143. Shuster S, Frost GI, Csoka AB, Formby B, Stern R. Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int J Cancer 2002; 102: 192-7.
144. Lokeshwar VB, Selzer MG. Hyaluronidase: both a tumor promoter and suppressor. Semin Cancer Biol 2008; 18: 281-7.
145. McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, et al. Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 2000; 276: 1170-7.
146. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 2000; 25: 349-51.
147. Goldshmidt O, Zcharia E, Aingorn H, Guatta-Rangini Z, Atzmon R, Michal I et al. Expression pattern sequence and secretion of human and chicken heparanase are determined by their signal peptide sequence. J Biol Chem 2001; 276: 29178-87.
148. Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, Metzger S et al. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 2005; 19: 211-21.
149. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, IshaiMichaeli R et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5: 793-802.
150. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108: 341-7.
151. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471: M99-108.
152. Fairbanks MB, Mildner AM, Leone JW, Cavey GS, Mathews WR, Drong RF et al. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J Biol Chem 1999; 274: 29587-90.
153. Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I, Ilan N. Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophy Res Commun 2003; 308: 885-91.
154. McKenzie E, Young K, Hircock M, Bennett J, Bhaman M, Felix R et al. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 2003; 373: 423-35.
155. Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H, Atzmon R, Elgavish S, Peretz T et al. Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem 2005; 280: 13568-75.
156. Abboud-Jarrous G, Atzmon R, Peretz T, Palermo C, Gadea BB, Joyce JA et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 2008; 283: 18167-76.
157. Hulett MD, Hornby JR, Ohms SJ, Zuegg J, Freeman C, Gready JE et al. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 2000; 39: 15659-67.
158. Reiland J, Sanderson RD, Waguespack M, Barker SA, Long R, Carson DD et al. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem 2004; 279: 8047-55.
159. Gilat D, Hershkoviz R, Goldkorn I, Cahalon L, Korner G, Vlodavsky I et al. Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH. J Exp Med 1995; 181: 1929-34.
160. Goldshmidt O, Zcharia E, Cohen M, Aingorn H, Cohen I, Nadav L et al. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 2003; 17: 1015-25.
161. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006; 66: 1455-63.
162. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 2006; 118: 1609-17.
163. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J 2001; 15: 1661-3.
164. Myler HA, Lipke EA, Rice EE, West JL. Novel heparanaseinhibiting antibody reduces neointima formation. J Biochem 2006; 139: 339-45.
165. Goldshmidt O, Zcharia E, Abrmovitch R, Metzger S, Ainghorn H, Friedmann Y et al. Cell surface expression and secretion of heparanase markedly promote angiogenesis and metastasis. Proc Natl Acad Sci U S A 2002; 99: 10031-6.
166. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 2004; 96: 1219-30.
167. Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 2007; 13: 2057-73.
168. Simizu S, Ishida K, Osada H. Heparanase as a molecular target of cancer chemotherapy. Cancer Sci 2004; 95: 553-8.
169. Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc) 2002; 67: 92-8.
170. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007; 97: 336-42.
171. Garcia-Touchard A, Henry TD, Sangiorgi G, Spagnoli LG, Mauriello A,
172. Pannell R, Gurewich V. Activation of plasminogen by single-chain urokinase or by two-chain urokinase: a demonstration that singlechain urokinase has a low catalytic activity (pro-urokinase). Blood 1987; 69: 22-8.
173. Petersen LC, Lund LR, Nielsen LS, Dano K, Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 1988; 263: 11189-95.
174. Hussain SS. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. Biochemistry 1991; 30: 5707-15.
175. Cubellis MV, Nolli ML, Cassani G, Blasi F. Binding of singlechain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem 1986; 261: 15189-22.
176. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinasetype plasminogen activator (Pro-uPA). J Biol Chem 1991; 266: 5147-52.
177. List K, Jensen ON, Bugge TH, Lund LR, Ploug M, Danø K et al. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen deficient mice. Biochemistry 2000; 39: 508-15.
178. Stepanova VV, Tkachuck VA. Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry (Mosc) 2002; 67: 109-18.
179. Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G et al. The receptor binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 1987; 262: 4437-40.
180. Quax PH, Grimbergen JM, Lansink M, Bakker AH, Blatter MC, van Hinsbergh VW et al. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding. Arterioscler Thromb Vasc Biol 1998; 18: 693-701.
181. Dass CR, Nadesapillai AP, Robin D, Howard ML, Fisher JL, Zhou H et al. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin Exp Metastasis 2005; 22: 643-52.
182. Liang X, Yang X, Tang Y, Zhou H, Liu X, Xiao L et al. RNAimediated downregulation of urokinase plasminogen activator receptors inhibits proliferation, adhesion, migration and invasion in oral cancer cells. Oral Oncol 2008; (Epub ahead of print).
183. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/ uPAR system in human cancers. Cancer Treat Rev 2008; 34: 122-36.
184. Szabo R, Netzel-Arnett S, Hobson JP, Antalis TM, Bugge TH. Matriptase-3 is a novel phylogenetically preserved membraneanchored serine protease with broad serpin reactivity. Biochem J 2005; 390: 231-42.
185. List K, Bugge TH, Szabo R. Matriptase: Potent Proteolysis on the Cell Surface. Mol Med 2006; 12: 1-7.
186. Sanders AJ, Parr C, Martin TA, Lane J, Mason MD, Jiang WG. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localization. J Cell Physiol 2008; 216: 780-9.
187. Lin CY, Tseng IC, Chou FP, Su SF, Chen YW, Johnson MD et al. Zymogen activation, inhibition, and ectodomain shedding of matriptase. Front Biosci 2008; 13: 621-35.
188. Velasco G, Cal S, Quesada V, Sánchez LM, López-Otin C. Matriptase- 2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J Biol Chem 2002; 277: 37637-46.
189. Jin X, Yagi M, Akiyama N, Hirosaki T, Higashi S, Lin CY et al. Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci 2006; 97: 1327-34.
190. Benaud CM, Oberst M, Dickson RB, Lin CY. Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 2002; 19: 639-49.
191. Bugge TH, List K, Szabo R. Matriptase-dependent cell surface proteolysis in epithelial development and pathogenesis. Front Biosci 2007; 12: 5060-70.
192. Emami N, Diamandis EP. Human tissue kallikreins: a road under construction. Clin Chim Acta 2007; 381: 78-84.
193. Debela M, Beaufort N, Magdolen V, Schechter NM, Craik CS, Schmitt M et al. Structures and specificity of the human kallikreinrelated peptidases KLK 4, 5, 6, and 7. Biol Chem 2008; 389: 623-32.
194. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endor Rev 2001; 22: 184-204.
195. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett 2005; 224: 1-22.
196. Yousef GM, Diamandis EP. Human tissue kallikreins: a new enzymatic cascade pathway? Biol Chem 2002; 383: 1045-57.
197. Rajapakse S, Ogiwara K, Takano N, Moriyama A, Takahashi T. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins. FEBS Lett 2005; 579: 6879-84.
198. Kapadia C, Ghosh MC, Grass L, Diamandis EP. Human kallikrein 13 involvement in extracellular matrix degradation. Biochem Biophys Res Commun 2004; 323: 1084-90.
199. Borgono CA, Michael IP, Shaw JL, Luo LY, Ghosh MC, Soosaipillai A et al. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem 2007; 282: 2405-22.
200. Ramani VC, Haun RS. The extracellular matrix protein fibronectin is a substrate for kallikrein 7. Biochem Biophys Res Commun 2008; 369: 1169-73.
201. Johnson SK, Ramani VC, Hennings L, Haun RS. Kallikrein 7 enhances pancreatice cancer cell invasion by shedding E-cadherin. Cancer 2007; 109: 1811-20.
202. Sang QX, Jin Y, Newcomer RG, Monroe SC, Fang X, Hurst DR, Lee S, Cao Q, Schwartz MA. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem. 2006; 6: 289-316. Review.
203. Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, Monroe HR, Sahab ZJ, Sang QX. Matrix metalloproteinase- 9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol. 2008; 9: 34-46. Review.